Clinical trials showed average weight loss of 20-25% of body weight with tirzepatide at the highest doses, compared to 15-17% with semaglutide
Peptide Therapy Your body naturally makes peptides that support your health and healing processes
Zepbound is not the diabetes-branded tirzepatide product Current FDA labeling indicates Zepbound for long-term weight reduction in adults with obesity or adults with overweight plus at least one weight-related condition, and for moderate-to-severe obstructive sleep apnea in adults with obesity
Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities
No evidence of hormonal, hepatic, or cardiovascular adverse effects has been observed in available data
Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors, distinguishing it from dual agonists like tirzepatide and single agonists like semaglutide